Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Medicine Guidelines
    • India Antibiotic...

    India Antibiotic Guideline For Febrile Neutropenia

    Written by supriya kashyap kashyap Published On 2016-09-25T09:04:45+05:30  |  Updated On 25 Sept 2016 9:04 AM IST
    India Antibiotic Guideline For Febrile Neutropenia

    In 2016 National Centre For Disease Control, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India came out with National Treatment Guidelines for Antimicrobial Use in Infectious Diseases.



    Following are major recommendation


    Febrile Neutropenia :


    Febrile Neutropenia- definition




    • Neutropenia-ANC<500/mm3 and expected to fall below 500/mm3 in 48hrs

    • Fever -single oral temperature of 38.3oC (1010 F) on one occasion or 38oC (100.40 F) on at least 2 occasions (1 hour apart)

    • Neutropenic patients may not have usual signs of infection. Redness, tenderness and fever may be the only signs.


    Protocol:




    • Critical examination of areas usually harboring infections, including but not limited to, oral cavity, axillary region, scalp, groin, perineal region.

    • Send blood Cultures 2 sets (each bottle 10ml x 4 bottles)

    • Other relevant investigations: urea, creatinine, ALT, urine culture, Chest Xray, separate culture from central line, etc


    Patient-Haemodynamically stable




    • Blood culture 2 sets

    • Start IV Ceftazidime

    • No need to add glycopeptide in the initial regimen (except in specific situations, given below)


    Patient-Haemodynamically unstable




    • Start BL-BLI agent (Cefoperazone-Sulbactam/piperacillin-tazobactam)


    OR




    • Carbapenem (meropenem/imipenem/doripenem)

    • No need to add glycopeptide in the initial regimen (except in specific situations, given below)


    Reassess after 48 hours:


    If blood cultures are negative, haemodynamically stable but still febrile




    • Reculture blood

    • Add amikacin for 3 days

    • Add colistin (instead of amikacin) if indicated (see below)


    If blood cultures are negative, haemodynamically unstable but still febrile




    • Inj Colistin (+/-Carbapenem) + glycopeptide + Echinocandin/L-Ampho


    B Blood culture growing Gram negative bacilli




    • Patient afebrile - continue the empirical antibiotic till antibiotic sensitivity is available.

    • Rationalise as per susceptibility profiles


    When to add glycopeptides?


    1. Haemodynamic instability, or other evidence of severe sepsis, septic shock or pneumonia


    2. Colonisation with MRSA or penicillin-resistant S. pneumonia 28


    3. Suspicion of serious catheter-related infectione.g. chills or rigours with infusion through catheter and cellulitis around the catheter exit site


    4. Skin or soft-tissue infection at any site


    5. Positive blood culture for gram-positive bacteria, before final identification and susceptibility testing is available


    6. Severe mucositis


    When to add empirical colistin in febrile neutropenic patients?


    1. Heamodynamic instability.


    2. Colonisation with carbapenem resistant gram-negative bacteria.


    3. Previous infection with carbapenem resistant gram-negative bacteria.


    4. GNB in blood, sensivity pending, persistent fever with haemodynamic instability.


    Empirical Antifungal Therapy




    • No response to broad spectrum antibiotics (3-5 days)-add L-Ampho B / echinocandin

    • When a patient is located at a remote area and may not have access to emergency healthcare services, febrile neutropenia can be lifethreatening. Under such circumstances, availability of broad-spectrum oral antibiotics with the patient can help them gain time to reach emergency healthcare service.


    Useful tips




    • Febrile after 72 hrs-CT chest and consider empirical antifungal.

    • If fever persists on empirical antibiotics, send two sets blood cultures/day for 2 days

    • Send further cultures if clinical deteriaration

    • Unexplained persistent fever in otherwise stable patient doesn’t require change in empirical antibiotic regimen. Continue the regimen till ANC is >500 cells/mm3

    • If glycopeptide started as a part of empirical regimen, STOP after 48 hrs, if no evidenc of Gram positive infection

    • Antibiotic treatment should be given for at least seven days with an apparently effective antibiotic, with at least four days without fever.

    • Once Neutrophil count has recovered, with no culture positivity and heamodynamically stable; antibiotics can be stopped and patient observed, even if remains febrile. Evaluate for fungal infection, if at risk.


    Antibiotic Prophylaxis


    Though quinolone prophylaxis is recommended by International guidleines, it is not useful in Indian scenario due to high resistance.


    Antiviral prophylaxis




    • For HSV IgG positive patients undergoing allo-HSCT or leukemia induction needs acyclovir prophylaxis

    • All patients being treated for cancer need to receive annual influenza vaccination with an inactivated vaccine.

    • Neutropenic patients presenting with influenza like illness should receive empirical treatment with neuraminidase inhibitor.


    Antifungal prophylaxis


    a) Induction chemotherapy of Acute Leukemia: Posoconazole


    b) Post allo BMT


    Pre engraftment: Voriconazole/echinocandin


    Post engraftment: Posoconazole


    You can read the full Guideline by clicking on the following link :


    http://www.ncdc.gov.in/writereaddata/linkimages/AMR_guideline7001495889.pdf

    febrile NeutropeniaGovernment of Indiainfectious diseaseMinistry of Health &amp; Family WelfareNational Centre For Disease

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok